same would seem to make a big difference in the eyes of veteran physicians. This
feature of flu follicles is that which cannot be discerned by just any doctor but only a
master doctor. Aillis Inc. is trying to reproduce the “eye of a master” with the power
of AI.
The research activity primarily conducted by Aillis has been adopted by a project
of the New Energy and Industrial Technology Development Organization (NEDO)
and has received financial support. The collection of key data began in 2018, and by
obtaining the first-class marketing authorization in 2019 from the Ministry of Health,
Labour and Welfare, it became possible for them to manufacture and sell various
medical devices. These included not only general medical devices (class I) that could
be manufactured and sold under the type III medical device manufacturing and
marketing license already acquired but also managed medical devices (class II) and
highly managed medical devices (classes III and IV), thus covering all the classifications of medical devices.
5.4 Genomic Medicine and AI
In cancer medicine, research using AI is rapidly becoming essential. We have
entered a time when cancer is classified not by the developmental organ or pathological classification but by the essential growth driver, that is, the gene mutation that
is essential for cancer growth.
Cancer occurs as a result of a change in nucleotide sequence caused by mutation
or a change in genome, resulting in the inability of a gene to function properly. Most
cancers are caused by smoking, lifestyle, aging, and other factors, and mutations in
certain somatic genes of normal cells give rise to cancer cells. When cancer progresses, this gene mutation is considered to be a source of progression and proliferation only in cancer cells.
Cancer genomic medicine is an attempt to investigate in detail the genes of cancer
that do not respond to usual treatment and cannot be removed by surgery and to
search for therapeutic agents that respond to changes in the gene. Anticancer drugs
called recent molecular target drugs are known to be effective against cancers with
certain special genetic changes. Although examining genes does not always lead to
treatment, if a drug with a molecular target is found, it may lead to long-term survival
or cure rather than continuing traditional treatment.
5.5 Oncogene Panel Test
The oncogene panel test is performed using an analysis device called the nextgeneration sequencer, which reads large amounts of genome information at high
speed using cancer tissues collected through biopsy or surgery. Multiple (several
tens to hundreds) genes can be examined simultaneously in one oncogenic panel test.
18
H. Matsushita
feature of flu follicles is that which cannot be discerned by just any doctor but only a
master doctor. Aillis Inc. is trying to reproduce the “eye of a master” with the power
of AI.
The research activity primarily conducted by Aillis has been adopted by a project
of the New Energy and Industrial Technology Development Organization (NEDO)
and has received financial support. The collection of key data began in 2018, and by
obtaining the first-class marketing authorization in 2019 from the Ministry of Health,
Labour and Welfare, it became possible for them to manufacture and sell various
medical devices. These included not only general medical devices (class I) that could
be manufactured and sold under the type III medical device manufacturing and
marketing license already acquired but also managed medical devices (class II) and
highly managed medical devices (classes III and IV), thus covering all the classifications of medical devices.
5.4 Genomic Medicine and AI
In cancer medicine, research using AI is rapidly becoming essential. We have
entered a time when cancer is classified not by the developmental organ or pathological classification but by the essential growth driver, that is, the gene mutation that
is essential for cancer growth.
Cancer occurs as a result of a change in nucleotide sequence caused by mutation
or a change in genome, resulting in the inability of a gene to function properly. Most
cancers are caused by smoking, lifestyle, aging, and other factors, and mutations in
certain somatic genes of normal cells give rise to cancer cells. When cancer progresses, this gene mutation is considered to be a source of progression and proliferation only in cancer cells.
Cancer genomic medicine is an attempt to investigate in detail the genes of cancer
that do not respond to usual treatment and cannot be removed by surgery and to
search for therapeutic agents that respond to changes in the gene. Anticancer drugs
called recent molecular target drugs are known to be effective against cancers with
certain special genetic changes. Although examining genes does not always lead to
treatment, if a drug with a molecular target is found, it may lead to long-term survival
or cure rather than continuing traditional treatment.
5.5 Oncogene Panel Test
The oncogene panel test is performed using an analysis device called the nextgeneration sequencer, which reads large amounts of genome information at high
speed using cancer tissues collected through biopsy or surgery. Multiple (several
tens to hundreds) genes can be examined simultaneously in one oncogenic panel test.
18
H. Matsushita